Last year, in a milestone for HIV prevention, the US Centers for Disease Control and Prevention formally recommended pre-exposure prophylaxis (PrEP), a novel HIV prevention strategy for people who are HIV-negative that involves taking a once-a-day pill and seeing a health care provider for routine visits. Since then, President Obama released an updated National HIV/AIDS Strategy which placed new emphasis on ensuring full access to PrEP and several states have developed programs to cover the cost of PrEP medication and related services. In the context of this new spotlight on PrEP, prescriptions have dramatically increased. However, this upsurge has primarily been seen in prescriptions for men. The number of new PrEP prescriptions for women has remained stagnant and woefully low. To put it plainly, PrEP is not reaching women. Read full article here.